Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a standard 40 mm needle reach the hip muscle in people with higher BMI?

NCT ID NCT07827300

Knowledge-focused Sponsor: Marmara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at Marmara University studied whether a 40 mm needle delivers medication into the ventrogluteal muscle in adults with a body mass index of 25 or higher. They used ultrasound to measure tissue thickness and watch the needle tip in real time during a vitamin B12 injection. The team checked how often the needle reached at least 10 mm below the muscle surface and stayed clear of the hip bone and sciatic nerve. They compared results across three body mass index groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cyanocobalamin (vitamin B12) injected into the ventrogluteal muscle with a 40 mm needle
What this could lead to
If the 40 mm needle reliably reaches muscle in people with higher body mass index, nurses could use a standard needle length with more confidence and fewer repeat injections.
What could go wrong
This is a small measurement study, not a test of whether the injection works better. Results may not apply to other needle lengths, injection sites, or people with different body shapes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

89 people

The number who actually took part.

Started

Apr 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 and \<75 years. * Body mass index \>24.9 kg/m². * A clinical order for intramuscular administration of 1 mL cyanocobalamin at a concentration of 1000 mcg/mL. * No muscle atrophy or motor or sensory loss associated with neurological or muscular pathology. * Able to walk independently or with assistance and perform activities of daily living. Exclusion Criteria: * Degenerative muscle diseases or motor neuron diseases. * Amyotrophic lateral sclerosis or other progressive neuromuscular diseases. * Severe muscle atrophy or motor function loss that could affect the reliability of ultrasonographic muscle-thickness measurements. * Muscle structure considered unsuitable for reliable ultrasonographic measurement or presence of motor/sensory function loss on clinical evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nursing care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nursing care Ventrogluteal injection

Contacts and locations

Locations

  • Bagcilar Training and Research Hospital

    Istanbul, Eyalet/Yerleşke, 34000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.